,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2018', 'fs': 'Mar 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000UYtfF2AT'}, 'Id': 'a0POZ00000UYtfF2AT', 'Event_Date__c': '2018-03-06', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Mar 2018', 'Status_History__c': 'a132P000000CpAuQAK'}, 'change': None}]",Mar 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2021', 'fs': 'May 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000UYtfG2AT'}, 'Id': 'a0POZ00000UYtfG2AT', 'Event_Date__c': '2021-05-06', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2021', 'Status_History__c': 'a132P000000CpAzQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2021', 'fs': 'Sep 2021', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Thursday 4 November 2021', 'fs': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Thursday 4 November 2021', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000UYtfH2AT'}, 'Id': 'a0POZ00000UYtfH2AT', 'Event_Date__c': '2021-09-01', 'Event_Description__c': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Thursday 4 November 2021', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2021', 'Status_History__c': 'a132P000000DaRIQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>8.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that ibrutinib for the treatment of first line Waldenström macroglobulinemia be listed with a <b>low</b> priority, within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">IBRUTINIB</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application – Waldenström Macroglobulinaemia (Lymphoplasmacytic Lymphoma)</b></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Applications only from a haematologist or any other medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months. </span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Prerequisites</b><span style=""font-size: 9pt;""> (tick boxes where appropriate):</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has Waldenström Macroglobulinaemia/Lymphoplasmacytic Lymphoma requiring treatment; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient is treatment naïve; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has good performance status.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Renewal application</b></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Applications only from a haematologist or any other medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months. </span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Prerequisites</b><span style=""font-size: 9pt;""> (tick boxes where appropriate) </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of clinical disease progression and </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains appropriate, and the patient is benefiting from treatment</span></p><p class=""ql-indent-1""><br></p><p>8.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee noted:</p><p class=""ql-indent-1"">8.5.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>the health need of people with WM requiring first line therapy, particularly in those who are unfit for immunochemotherapy and the currently funded treatment options for this population group</p><p class=""ql-indent-1"">8.5.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>the evidence of benefit and improved tolerability of ibrutinib over currently funded treatments for people with WM; although the Subcommittee recognised the absence of direct comparator randomised controlled trials</p><p class=""ql-indent-1"">8.5.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>the improved suitability of an oral treatment option for this patient group if used as monotherapy</p>', 'fs': '<p>8.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that ibrutinib for the treatment of first line Waldenström macroglobulinemia be listed with a <b>low</b> priority, within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">IBRUTINIB</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application – Waldenström Macroglobulinaemia (Lymphoplasmacytic Lymphoma)</b></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Applications only from a haematologist or any other medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months. </span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Prerequisites</b><span style=""font-size: 9pt;""> (tick boxes where appropriate):</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has Waldenström Macroglobulinaemia/Lymphoplasmacytic Lymphoma requiring treatment; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient is treatment naïve; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has good performance status.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Renewal application</b></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Applications only from a haematologist or any other medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months. </span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Prerequisites</b><span style=""font-size: 9pt;""> (tick boxes where appropriate) </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of clinical disease progression and </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains appropriate, and the patient is benefiting from treatment</span></p><p class=""ql-indent-1""><br></p><p>8.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee noted:</p><p class=""ql-indent-1"">8.5.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>the health need of people with WM requiring first line therapy, particularly in those who are unfit for immunochemotherapy and the currently funded treatment options for this population group</p><p class=""ql-indent-1"">8.5.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>the evidence of benefit and improved tolerability of ibrutinib over currently funded treatments for people with WM; although the Subcommittee recognised the absence of direct comparator randomised controlled trials</p><p class=""ql-indent-1"">8.5.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>the improved suitability of an oral treatment option for this patient group if used as monotherapy</p>', 'change': None}, 'Published_Discussion': {'s': '<p>8.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the supplier had submitted an abbreviated clinical summary in 2018 to consider funding ibrutinib for patients with WM, which had not previously been considered by CaTSoP or PTAC. The Subcommittee noted that there have been no previous considerations of specific treatments for WM in isolation, however Pharmac currently funds several treatments for patients with indolent lymphomas (eg WM), including bendamustine and rituximab (funded under Special Authority).</p><p>8.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lymphoplasmacytic lymphoma is an incurable low-grade B-cell non-Hodgkin lymphoma characterised by the infiltration of bone marrow +/-spleen or lymph nodes by a clonal B cell population. The Subcommittee noted that when lymphoplasmacytic lymphoma is associated with an IgM paraprotein, it is referred to as Waldenström macroglobulinemia. For the purposes of the record, WM will be used to reference both lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia. (<a href=""https://www.leukaemia.org.au/blood-cancer-information/types-of-blood-cancer/waldenstroms-macroglobulinaemia/"" target=""_blank"">Leukaemia Foundation Australia 2021</a>).</p><p>8.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that WM is a heterogenous condition. The Subcommittee noted that asymptomatic patients should undergo monitoring and only require treatment if symptomatic disease develops. The Subcommittee noted that WM can cause anaemia, pancytopenia, symptomatic organomegaly or B-symptoms from tissue infiltration, and that symptomatic disease can result from IgM paraprotein associated disorders including hyperviscosity, cold agglutinin disease, peripheral neuropathy, or cryoglobulinaemia. The Subcommittee noted that these symptoms may impact an individual’s quality of life and ability to carry out daily activities. Some complications of WM require urgent therapy, such as symptomatic hyperviscosity, moderate to severe haemolytic anaemia, and symptomatic cryoglobulinemia. The Subcommittee noted that WM is a progressive disease that results in impaired function and quality of life and can lead to early death.</p><p>8.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted international estimates of WM incidence of 2-3 cases per million. The Subcommittee noted the supplier’s estimate of approximately 12 patients diagnosed with relapsed/refractory WM per year in New Zealand. The Subcommittee considered this to be an underestimate, and that patient numbers in New Zealand could be double that estimated by the supplier. The Subcommittee noted WM is more common in men, and predominantly diagnosed in older patients with a median age at diagnosis of 68 years (<a href=""https://www.leukaemia.org.au/blood-cancer-information/types-of-blood-cancer/waldenstroms-macroglobulinaemia/"" target=""_blank"">Leukaemia Foundation Australia 2021</a>). The Subcommittee noted that the relative incidence of WM in Māori and other disadvantaged groups compared to non-Māori was uncertain.</p><p>8.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the currently funded treatments for those with WM include bendamustine-rituximab (preferred option), and rituximab- cyclophosphamide-dexamethasone (DRC), or rituximab monotherapy (in those with comorbidities or low tumour burden). The Subcommittee noted that the median progression free survival (PFS) is 69.5 months for\xa0bendamustine-rituximab treatment (<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61763-2/fulltext"" target=""_blank"">Rummel et al. Lancet. 2013;381:1203-1210</a>), 34 months (95% CI 23 to ‘not reached’) for first line DRC treatment (<a href=""https://ashpublications.org/blood/article/126/11/1392/34400/Dexamethasone-rituximab-and-cyclophosphamide-as"" target=""_blank"">Kastritis et al. Blood. 2015;126:1392-1394</a>),), and 35 months (95% CI 15 to 51) for DRC treatment in relapsed/refractory patients (<a href=""https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14826"" target=""_blank"">Paludo et al. BJH. 2017;179:98-105</a>), and 20.3 months for 8 cycles of single agent rituximab (comparator arm of iNNOVATE trial). The Subcommittee considered that patients with relapsed/refractory WM can be retreated with the previous chemotherapy regimen if this was effective in the previous line, an alternative chemotherapy regimen, or rituximab monotherapy. The Subcommittee considered that efficacy of treatment and PFS with each successive line of treatment would be expected to diminish. The Subcommittee noted that autologous or allogenic transplantation were infrequent therapies for patients with WM.</p><p>8.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following publications as evidence of the use of currently funded agents for the treatment of WM:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.dovepress.com/rituximab-based-combination-therapy-in-patients-with-waldenstroumlm-ma-peer-reviewed-fulltext-article-OTT"" target=""_blank"">Zheng et al. Onco Targets Ther. 2019;12:2751-2766</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Walewski et al. Br J Haematol. 2020;188;898-906</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.15718"" target=""_blank"">Laribi et al. Br J Haematol. 2018;186:146-149</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ashpublications.org/blood/article/126/11/1392/34400/Dexamethasone-rituximab-and-cyclophosphamide-as"" target=""_blank"">Kastritis et al. Blood. 2015;126:1392-4</a></p><p>8.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that bortezomib in combination with dexamethasone +/- rituximab has also been shown to be efficacious in patients with WM. It was noted that the long term follow up of a phase II study of bortezomib, dexamethasone, and rituximab (BDR) has shown a median PFS of 3.5 years, median duration of major response of 5.5 years, and OS rate of 66% at 7 years (<a href=""https://www.annalsofoncology.org/article/S0923-7534(19)31695-3/pdf"" target=""_blank"">Kastritis et al. ESMO. 2018</a>; <a href=""https://ashpublications.org/blood/article/129/4/456/36177/BDR-in-newly-diagnosed-patients-with-WM-final"" target=""_blank"">Gavriatopoulou et al. Blood. 2017;4:456-459</a>). The Subcommittee noted that bortezomib is not currently funded for people with WM and considered that it would like to review bortezomib for the treatment of patients with WM at a future Cancer Treatments Subcommittee meeting.</p><p>8.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted elderly patients with WM are more likely to have poorer outcomes due to their increased frailty, comorbidities, and susceptibility to developing adverse reactions to chemotherapy (<a href=""https://ashpublications.org/blood/article/113/18/4163/25738/International-prognostic-scoring-system-for"" target=""_blank"">Morel et al. Blood. 2009;113:4163-70</a>). The Subcommittee also noted those with WM living in rural areas are more likely to experience difficulty in accessing treatment services and thereby more at risk of experiencing poor survival and health outcomes. The Subcommittee considered that the availability of an effective oral treatment option for this patient group would be particularly beneficial.</p><p>8.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the treatment options (rituximab in combination with chemotherapy) to be effective for fit patients with WM and therefore the health need for this group of treatment naïve patients was comparatively low. The Subcommittee considered that the health need for patients with WM is greater for those who are unfit or unable to receive rituximab in combination with chemotherapy due to their frailty or comorbidities, as well as those who have relapsed after, or are refractory to a prior line of treatment, due to the limited treatment options and shorter PFS in later lines of treatment.</p><p>8.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that ibrutinib is an inhibitor of Bruton tyrosine kinase (BTK), and effectively inhibits B-cell receptor and cytokine receptor pathways, thereby hindering malignant B-cell proliferation and survival <i>in vivo</i> as well as cell migration and substrate adhesion in vitro. The Subcommittee noted that <a href=""https://www.medsafe.govt.nz/regulatory/ProductDetail.asp?ID=17325"" target=""_blank"">ibrutinib is Medsafe approved</a> for the treatment of patients with WM. The Subcommittee noted that the recommended dose of ibrutinib for WM is 420mg (three 140mg capsules) once daily until disease progression or if no longer tolerated by the patient, administered either as monotherapy or in combination with rituximab.</p><p>8.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that as ibrutinib can be self-administered by the patient or caregiver in the community, the burden of treatment delivery and need for repeated attendance at a hospital or outpatient facility would be reduced.</p><p>8.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the key evidence for ibrutinib in the treatment of WM comes from two clinical trials, PCYC-1127-CA (iNNOVATE) and PCYC-1118E.</p><p>8.18<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted that the iNNOVATE trial was a phase III randomised, double-blind, placebo-controlled trial which investigated ibrutinib plus rituximab compared to placebo plus rituximab in 150 adults with previously untreated (n=68) or treated (n=82) WM.</p><p class=""ql-indent-1"">8.18.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted the results of the final analysis of the iNNOVATE trial after a median follow up of 50 (range 0.5-63) months. The Subcommittee noted that the overall median PFS was not reached (95% CI 57.7 months to ‘not evaluable’ [NE]) in the ibrutinib-rituximab group and 20.3 months (95% CI 13.0 to 27.6) in the placebo-rituximab group. The Subcommittee noted that the median time to next treatment was not reached in the ibrutinib-rituximab group and 18 months in the placebo-rituximab group. The Subcommittee noted that the overall survival (OS) was not reached in either arm. The Subcommittee noted that the ibrutinib-rituximab group had a sustained haemoglobin improvement of 77% versus 43% in the placebo-rituximab group (P&lt;0.0001) (<a href=""https://ascopubs.org/doi/full/10.1200/JCO.21.00838"" target=""_blank"">Buske et al. J Clin Oncol. 2021</a>).</p><p class=""ql-indent-1"">8.18.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that in previously untreated patients, the 54-month PFS rate was not reached in either the ibrutinib-rituximab or placebo-rituximab arm, and that the 48-month PFS rate in these subgroups was 70% and 32%, respectively. It was noted that in previously treated patients, the 54-month PFS rate was 68% with ibrutinib-rituximab versus 20% with placebo-rituximab, with 48-month PFS rates of 71% and 20%, respectively. The Subcommittee noted that ibrutinib-rituximab treatment significantly reduced risk of progression or death versus placebo-rituximab across all prespecified subgroups within the previously treated population, including by serum IgM level, haemoglobin level, and MYD88 mutational status, and within most of these subgroups in the previously untreated population.</p><p class=""ql-indent-1"">8.18.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that serious adverse events (AEs) occurred in 53% of the ibrutinib-rituximab group, 33% of the placebo-rituximab group, and 52% of the ibrutinib substudy group. The Subcommittee noted that the most common AEs in the ibrutinib substudy group were infections (47% at years 3-4; 50% at years 4-5), hypertension (29% at years 3-4; 36% at years 4-5), and diarrhoea (24% in years 3-4; 7% in years 4-5). The Subcommittee noted that 7 patients in the ibrutinib-rituximab group and 34 patients in the placebo-rituximab group discontinued treatment due to disease progression.</p><p class=""ql-indent-1"">8.18.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted 31 patients from the iNNOVATE trial who were refractory to treatment with rituximab were enrolled into an open label ibrutinib monotherapy substudy. The Subcommittee noted the results of the final analysis of the open label ibrutinib monotherapy substudy after a median follow up of 58 (range 9-61) months. The Subcommittee noted that the median PFS was 39 months (95% CI 25 to NE), with an estimated 18-month PFS of 86% and estimated 60-month PFS rate of 40%. The median OS was not reached (95% CI NE to NE) and the 60-month OS rate was 73% <a href=""https://clincancerres.aacrjournals.org/content/early/2021/08/17/1078-0432.CCR-21-1497.full-text.pdf"" target=""_blank"">Trotman et al. Clin Cancer Res. 2021</a>).</p><p>8.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted the following additional publications on the iNNOVATE trial:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30632-5/fulltext"" target=""_blank"">Dimopoulos et al. Lancet Oncol. 2017;18:241-250.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.nejm.org/doi/10.1056/NEJMoa1802917?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov"" target=""_blank"">Dimopoulos et al. N Engl J Med. 2018;378:2399-2410.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8018"" target=""_blank"">Trotman et al. EHA. 2017 abstract.</a></p><p>8.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the PCYC-1118E trial was a phase II open-label, prospective, single agent study which investigated ibrutinib monotherapy until disease progression or unacceptable toxicity in 63 symptomatic adults with WM who have received at least one prior treatment (median of two prior treatments) (<a href=""https://ascopubs.org/doi/10.1200/JCO.20.00555?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed"" target=""_blank"">Treon et al. J Clin Oncol. 2021;39:565-575.</a>; <a href=""https://www.nejm.org/doi/10.1056/NEJMoa1501548?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov"" target=""_blank"">Treon et al. N Engl J Med. 2015; 372:1430-40.</a>). The Subcommittee noted that after a median follow up of 59 months (95% CI 40 to 60), the 5-year PFS was 54% (95% CI 39 to 67) and the 5-year OS was 87%. The Subcommittee noted that the overall response rate (ORR) was 90.5% and the major response rate was 79.4%. The Subcommittee noted that the most common grade 3 or higher AEs that occurred in more than one patient were neutropenia (15.9%), thrombocytopenia (11.1%), and pneumonia (3.2%). The Subcommittee noted that atrial fibrillation occurred in eight patients (12.7%) overall at a median of 15 months (range 3-38 months) after starting treatment.</p><p>8.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that Castillo et al 2021 reported on a phase II, single centre, prospective, single arm study which investigated ibrutinib monotherapy in 30 treatment naïve patients with WM (<a href=""https://www.nature.com/articles/s41375-021-01417-9"" target=""_blank"">Castillo et al. Leukaemia. 2021</a>). The Subcommittee noted that after a median follow up of 50 months, the median PFS was not reached and the 4-year PFS rate was 76%, and there was a non-significant lower 4-year PFS rate in patients with than without CXCR4 mutations (59% versus 92%; P=0.06). The Subcommittee noted that the most common treatment-related AEs were fatigue, upper respiratory infection, and hematoma, and that atrial fibrillation occurred in 20% of patients.</p><p>8.22<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the additional evidence supporting the use of ibrutinib for patients with WM:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""http://www.waldenstroms.com/images/news/ASH-2017/12-11-2017-PUB4051.pdf"" target=""_blank"">Gustine, J., K. Meid, and T. Dubeau. American Society of Hematology. 2017 abstract</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.semanticscholar.org/paper/Ibrutinib-Is-Highly-Active-As-First-Line-Therapy-in-Treon-Gustine/b5b5f8b55a1a4109ea279d6318736350219fc4ad"" target=""_blank"">Treon et al. ASH. 2017 abstract</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306303/"" target=""_blank"">Castillo et al. Hemasphere. 2020;4</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31184501/"" target=""_blank"">Grunenberg et al. Future Oncol. 2019;15:2687-2697.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32603202/"" target=""_blank"">Lim et al. Expert Opin Pharmacother. 2020;21:1555-1564.</a></p><p>8.23<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the evidence provided supports the efficacy of ibrutinib for the treatment of first line and relapsed/refractory WM. The Subcommittee however considered that this evidence was limited, in that it does not include randomised controlled trials comparing ibrutinib to relevant rituximab combination chemotherapy (ie. bendamustine-rituximab or DRC). The Subcommittee considered that the efficacy of rituximab in combination with chemotherapy would be considerably greater than the comparator treatment in the iNNOVATE trial (rituximab monotherapy). The Subcommittee considered the efficacy (PFS) of ibrutinib for patients with previously untreated WM to be somewhat comparable to that of bendamustine-rituximab. The Subcommittee considered that in the absence of direct comparative trials, the benefit of ibrutinib over such comparators is uncertain.</p><p>8.24<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the toxicity profile of ibrutinib to be manageable and less than that of other currently funded treatments. The Subcommittee considered that the reduced toxicity and reduced treatment burden may correspond to a health-related quality of life benefit. The Subcommittee also considered the improved suitability of ibrutinib as an oral treatment as it allows treatment in the community and management of patients as outpatients. The Subcommittee considered that, when used in combination with rituximab, outpatient attendance for systemic rituximab treatment would be required for up to 8 cycles. The Subcommittee considered that comparators for ibrutinib were of fixed duration (6 cycles) of systemic therapy versus continuous therapy with ibrutinib.</p><p>8.25<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that for first line treatment of WM, ibrutinib would be of most benefit and may improve PFS for those with comorbidities who are unfit for more intensive rituximab-based chemotherapy regimens. The Subcommittee considered that this patient group would equate to approximately 25% of those with previously untreated WM but that this may vary depending on clinician preference.</p><p>8.26<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there is unlikely to be new evidence for the use of ibrutinib for patients with WM, as BTK inhibitors are the standard of care for these patients in other international jurisdictions.</p><p>8.27<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that ibrutinib would be of particular benefit and would improve PFS for those with WM who relapse early after or are refractory to rituximab-based chemotherapy, as these individuals have very limited current treatment options.</p><p>8.28<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the publications below of key clinical trial evidence for other BTK inhibitors for the treatment of WM to assess whether there is a class effect. The Subcommittee considered that a class effect is likely, with each BTK inhibitor presenting differing side effect profiles. The Subcommittee considered that it would welcome a funding application for the use of other BTK inhibitors for this patient group.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ashpublications.org/blood/article/136/18/2038/461625/A-randomized-phase-3-trial-of-zanubrutinib-vs"" target=""_blank"">Constantine et al. Blood. 2020;136:2038-2050.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://onlinelibrary.wiley.com/doi/10.1111/cas.14561"" target=""_blank"">Sekiguchi et al. Cancer Sci. 2020;111:3327-3337.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30210-8/fulltext"" target=""_blank"">Owen et al. Lancet Haematol. 2020;7:112-121.</a></p><p>8.29<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the response to ibrutinib treatment may also depend on the identified WM mutation subtype and that those with CXCR4 mutations may benefit more than other populations. The Subcommittee considered that CXCR4 subtyping is not currently included in routine WM testing. The Subcommittee considered that there may be changes in health sector expenditure if ibrutinib were funded, with increased testing for CXCR4 mutations to determine treatment preference especially for first line therapy.\xa0</p><p>8.30<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered other health sector expenditure costs of ibrutinib would include additional clinic follow up for continuous therapy, outpatient care to manage side effects, and pharmacy dispensing services.</p><p>8.31<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that if funded, the number of patients receiving ibrutinib would increase over time due to continuous therapy and the long PFS. The Subcommittee considered that the estimated duration of treatment of 47.7 months used to assess the budget impact of ibrutinib is likely an underestimate and considered that patients with WM would likely continue treatment for longer than this. The Subcommittee noted that in the iNNOVATE trial, 45% of patients continued to receive ibrutinib in a commercial setting post-study, indicating that the duration of treatment may be much longer. The Subcommittee considered that if ibrutinib were funded, New Zealand patients may have lower discontinuation rates compared to that seen overseas and in clinical trials due to the lack of other currently funded treatment options available for WM. The Subcommittee considered that the treatment duration and disease course of WM is probably similar to the more well-evidenced CLL patient group treated with BTK inhibitors.</p><p>8.32<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that comparator treatments for patients who could receive rituximab in combination with chemotherapy would require fewer than two lines of treatment of finite duration over 5 years, consistent with the median PFS of 70 months for patients receiving bendamustine-rituximab and thus the relative cost of treatment compared with ibrutinib would likely be substantially less.</p><p>8.33<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for ibrutinib if it were to be funded in New Zealand for WM. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Subcommittee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.<span style=""color: black;""> </span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000UYtfI&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000001vfyj"" alt=""image.png""></img></p>', 'fs': '<p>8.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the supplier had submitted an abbreviated clinical summary in 2018 to consider funding ibrutinib for patients with WM, which had not previously been considered by CaTSoP or PTAC. The Subcommittee noted that there have been no previous considerations of specific treatments for WM in isolation, however Pharmac currently funds several treatments for patients with indolent lymphomas (eg WM), including bendamustine and rituximab (funded under Special Authority).</p><p>8.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lymphoplasmacytic lymphoma is an incurable low-grade B-cell non-Hodgkin lymphoma characterised by the infiltration of bone marrow +/-spleen or lymph nodes by a clonal B cell population. The Subcommittee noted that when lymphoplasmacytic lymphoma is associated with an IgM paraprotein, it is referred to as Waldenström macroglobulinemia. For the purposes of the record, WM will be used to reference both lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia. (<a href=""https://www.leukaemia.org.au/blood-cancer-information/types-of-blood-cancer/waldenstroms-macroglobulinaemia/"" target=""_blank"">Leukaemia Foundation Australia 2021</a>).</p><p>8.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that WM is a heterogenous condition. The Subcommittee noted that asymptomatic patients should undergo monitoring and only require treatment if symptomatic disease develops. The Subcommittee noted that WM can cause anaemia, pancytopenia, symptomatic organomegaly or B-symptoms from tissue infiltration, and that symptomatic disease can result from IgM paraprotein associated disorders including hyperviscosity, cold agglutinin disease, peripheral neuropathy, or cryoglobulinaemia. The Subcommittee noted that these symptoms may impact an individual’s quality of life and ability to carry out daily activities. Some complications of WM require urgent therapy, such as symptomatic hyperviscosity, moderate to severe haemolytic anaemia, and symptomatic cryoglobulinemia. The Subcommittee noted that WM is a progressive disease that results in impaired function and quality of life and can lead to early death.</p><p>8.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted international estimates of WM incidence of 2-3 cases per million. The Subcommittee noted the supplier’s estimate of approximately 12 patients diagnosed with relapsed/refractory WM per year in New Zealand. The Subcommittee considered this to be an underestimate, and that patient numbers in New Zealand could be double that estimated by the supplier. The Subcommittee noted WM is more common in men, and predominantly diagnosed in older patients with a median age at diagnosis of 68 years (<a href=""https://www.leukaemia.org.au/blood-cancer-information/types-of-blood-cancer/waldenstroms-macroglobulinaemia/"" target=""_blank"">Leukaemia Foundation Australia 2021</a>). The Subcommittee noted that the relative incidence of WM in Māori and other disadvantaged groups compared to non-Māori was uncertain.</p><p>8.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the currently funded treatments for those with WM include bendamustine-rituximab (preferred option), and rituximab- cyclophosphamide-dexamethasone (DRC), or rituximab monotherapy (in those with comorbidities or low tumour burden). The Subcommittee noted that the median progression free survival (PFS) is 69.5 months for\xa0bendamustine-rituximab treatment (<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61763-2/fulltext"" target=""_blank"">Rummel et al. Lancet. 2013;381:1203-1210</a>), 34 months (95% CI 23 to ‘not reached’) for first line DRC treatment (<a href=""https://ashpublications.org/blood/article/126/11/1392/34400/Dexamethasone-rituximab-and-cyclophosphamide-as"" target=""_blank"">Kastritis et al. Blood. 2015;126:1392-1394</a>),), and 35 months (95% CI 15 to 51) for DRC treatment in relapsed/refractory patients (<a href=""https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14826"" target=""_blank"">Paludo et al. BJH. 2017;179:98-105</a>), and 20.3 months for 8 cycles of single agent rituximab (comparator arm of iNNOVATE trial). The Subcommittee considered that patients with relapsed/refractory WM can be retreated with the previous chemotherapy regimen if this was effective in the previous line, an alternative chemotherapy regimen, or rituximab monotherapy. The Subcommittee considered that efficacy of treatment and PFS with each successive line of treatment would be expected to diminish. The Subcommittee noted that autologous or allogenic transplantation were infrequent therapies for patients with WM.</p><p>8.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following publications as evidence of the use of currently funded agents for the treatment of WM:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.dovepress.com/rituximab-based-combination-therapy-in-patients-with-waldenstroumlm-ma-peer-reviewed-fulltext-article-OTT"" target=""_blank"">Zheng et al. Onco Targets Ther. 2019;12:2751-2766</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Walewski et al. Br J Haematol. 2020;188;898-906</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.15718"" target=""_blank"">Laribi et al. Br J Haematol. 2018;186:146-149</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ashpublications.org/blood/article/126/11/1392/34400/Dexamethasone-rituximab-and-cyclophosphamide-as"" target=""_blank"">Kastritis et al. Blood. 2015;126:1392-4</a></p><p>8.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that bortezomib in combination with dexamethasone +/- rituximab has also been shown to be efficacious in patients with WM. It was noted that the long term follow up of a phase II study of bortezomib, dexamethasone, and rituximab (BDR) has shown a median PFS of 3.5 years, median duration of major response of 5.5 years, and OS rate of 66% at 7 years (<a href=""https://www.annalsofoncology.org/article/S0923-7534(19)31695-3/pdf"" target=""_blank"">Kastritis et al. ESMO. 2018</a>; <a href=""https://ashpublications.org/blood/article/129/4/456/36177/BDR-in-newly-diagnosed-patients-with-WM-final"" target=""_blank"">Gavriatopoulou et al. Blood. 2017;4:456-459</a>). The Subcommittee noted that bortezomib is not currently funded for people with WM and considered that it would like to review bortezomib for the treatment of patients with WM at a future Cancer Treatments Subcommittee meeting.</p><p>8.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted elderly patients with WM are more likely to have poorer outcomes due to their increased frailty, comorbidities, and susceptibility to developing adverse reactions to chemotherapy (<a href=""https://ashpublications.org/blood/article/113/18/4163/25738/International-prognostic-scoring-system-for"" target=""_blank"">Morel et al. Blood. 2009;113:4163-70</a>). The Subcommittee also noted those with WM living in rural areas are more likely to experience difficulty in accessing treatment services and thereby more at risk of experiencing poor survival and health outcomes. The Subcommittee considered that the availability of an effective oral treatment option for this patient group would be particularly beneficial.</p><p>8.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the treatment options (rituximab in combination with chemotherapy) to be effective for fit patients with WM and therefore the health need for this group of treatment naïve patients was comparatively low. The Subcommittee considered that the health need for patients with WM is greater for those who are unfit or unable to receive rituximab in combination with chemotherapy due to their frailty or comorbidities, as well as those who have relapsed after, or are refractory to a prior line of treatment, due to the limited treatment options and shorter PFS in later lines of treatment.</p><p>8.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that ibrutinib is an inhibitor of Bruton tyrosine kinase (BTK), and effectively inhibits B-cell receptor and cytokine receptor pathways, thereby hindering malignant B-cell proliferation and survival <i>in vivo</i> as well as cell migration and substrate adhesion in vitro. The Subcommittee noted that <a href=""https://www.medsafe.govt.nz/regulatory/ProductDetail.asp?ID=17325"" target=""_blank"">ibrutinib is Medsafe approved</a> for the treatment of patients with WM. The Subcommittee noted that the recommended dose of ibrutinib for WM is 420mg (three 140mg capsules) once daily until disease progression or if no longer tolerated by the patient, administered either as monotherapy or in combination with rituximab.</p><p>8.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that as ibrutinib can be self-administered by the patient or caregiver in the community, the burden of treatment delivery and need for repeated attendance at a hospital or outpatient facility would be reduced.</p><p>8.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the key evidence for ibrutinib in the treatment of WM comes from two clinical trials, PCYC-1127-CA (iNNOVATE) and PCYC-1118E.</p><p>8.18<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted that the iNNOVATE trial was a phase III randomised, double-blind, placebo-controlled trial which investigated ibrutinib plus rituximab compared to placebo plus rituximab in 150 adults with previously untreated (n=68) or treated (n=82) WM.</p><p class=""ql-indent-1"">8.18.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted the results of the final analysis of the iNNOVATE trial after a median follow up of 50 (range 0.5-63) months. The Subcommittee noted that the overall median PFS was not reached (95% CI 57.7 months to ‘not evaluable’ [NE]) in the ibrutinib-rituximab group and 20.3 months (95% CI 13.0 to 27.6) in the placebo-rituximab group. The Subcommittee noted that the median time to next treatment was not reached in the ibrutinib-rituximab group and 18 months in the placebo-rituximab group. The Subcommittee noted that the overall survival (OS) was not reached in either arm. The Subcommittee noted that the ibrutinib-rituximab group had a sustained haemoglobin improvement of 77% versus 43% in the placebo-rituximab group (P&lt;0.0001) (<a href=""https://ascopubs.org/doi/full/10.1200/JCO.21.00838"" target=""_blank"">Buske et al. J Clin Oncol. 2021</a>).</p><p class=""ql-indent-1"">8.18.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that in previously untreated patients, the 54-month PFS rate was not reached in either the ibrutinib-rituximab or placebo-rituximab arm, and that the 48-month PFS rate in these subgroups was 70% and 32%, respectively. It was noted that in previously treated patients, the 54-month PFS rate was 68% with ibrutinib-rituximab versus 20% with placebo-rituximab, with 48-month PFS rates of 71% and 20%, respectively. The Subcommittee noted that ibrutinib-rituximab treatment significantly reduced risk of progression or death versus placebo-rituximab across all prespecified subgroups within the previously treated population, including by serum IgM level, haemoglobin level, and MYD88 mutational status, and within most of these subgroups in the previously untreated population.</p><p class=""ql-indent-1"">8.18.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that serious adverse events (AEs) occurred in 53% of the ibrutinib-rituximab group, 33% of the placebo-rituximab group, and 52% of the ibrutinib substudy group. The Subcommittee noted that the most common AEs in the ibrutinib substudy group were infections (47% at years 3-4; 50% at years 4-5), hypertension (29% at years 3-4; 36% at years 4-5), and diarrhoea (24% in years 3-4; 7% in years 4-5). The Subcommittee noted that 7 patients in the ibrutinib-rituximab group and 34 patients in the placebo-rituximab group discontinued treatment due to disease progression.</p><p class=""ql-indent-1"">8.18.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted 31 patients from the iNNOVATE trial who were refractory to treatment with rituximab were enrolled into an open label ibrutinib monotherapy substudy. The Subcommittee noted the results of the final analysis of the open label ibrutinib monotherapy substudy after a median follow up of 58 (range 9-61) months. The Subcommittee noted that the median PFS was 39 months (95% CI 25 to NE), with an estimated 18-month PFS of 86% and estimated 60-month PFS rate of 40%. The median OS was not reached (95% CI NE to NE) and the 60-month OS rate was 73% <a href=""https://clincancerres.aacrjournals.org/content/early/2021/08/17/1078-0432.CCR-21-1497.full-text.pdf"" target=""_blank"">Trotman et al. Clin Cancer Res. 2021</a>).</p><p>8.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted the following additional publications on the iNNOVATE trial:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30632-5/fulltext"" target=""_blank"">Dimopoulos et al. Lancet Oncol. 2017;18:241-250.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.nejm.org/doi/10.1056/NEJMoa1802917?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov"" target=""_blank"">Dimopoulos et al. N Engl J Med. 2018;378:2399-2410.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8018"" target=""_blank"">Trotman et al. EHA. 2017 abstract.</a></p><p>8.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the PCYC-1118E trial was a phase II open-label, prospective, single agent study which investigated ibrutinib monotherapy until disease progression or unacceptable toxicity in 63 symptomatic adults with WM who have received at least one prior treatment (median of two prior treatments) (<a href=""https://ascopubs.org/doi/10.1200/JCO.20.00555?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed"" target=""_blank"">Treon et al. J Clin Oncol. 2021;39:565-575.</a>; <a href=""https://www.nejm.org/doi/10.1056/NEJMoa1501548?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov"" target=""_blank"">Treon et al. N Engl J Med. 2015; 372:1430-40.</a>). The Subcommittee noted that after a median follow up of 59 months (95% CI 40 to 60), the 5-year PFS was 54% (95% CI 39 to 67) and the 5-year OS was 87%. The Subcommittee noted that the overall response rate (ORR) was 90.5% and the major response rate was 79.4%. The Subcommittee noted that the most common grade 3 or higher AEs that occurred in more than one patient were neutropenia (15.9%), thrombocytopenia (11.1%), and pneumonia (3.2%). The Subcommittee noted that atrial fibrillation occurred in eight patients (12.7%) overall at a median of 15 months (range 3-38 months) after starting treatment.</p><p>8.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that Castillo et al 2021 reported on a phase II, single centre, prospective, single arm study which investigated ibrutinib monotherapy in 30 treatment naïve patients with WM (<a href=""https://www.nature.com/articles/s41375-021-01417-9"" target=""_blank"">Castillo et al. Leukaemia. 2021</a>). The Subcommittee noted that after a median follow up of 50 months, the median PFS was not reached and the 4-year PFS rate was 76%, and there was a non-significant lower 4-year PFS rate in patients with than without CXCR4 mutations (59% versus 92%; P=0.06). The Subcommittee noted that the most common treatment-related AEs were fatigue, upper respiratory infection, and hematoma, and that atrial fibrillation occurred in 20% of patients.</p><p>8.22<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the additional evidence supporting the use of ibrutinib for patients with WM:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""http://www.waldenstroms.com/images/news/ASH-2017/12-11-2017-PUB4051.pdf"" target=""_blank"">Gustine, J., K. Meid, and T. Dubeau. American Society of Hematology. 2017 abstract</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.semanticscholar.org/paper/Ibrutinib-Is-Highly-Active-As-First-Line-Therapy-in-Treon-Gustine/b5b5f8b55a1a4109ea279d6318736350219fc4ad"" target=""_blank"">Treon et al. ASH. 2017 abstract</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306303/"" target=""_blank"">Castillo et al. Hemasphere. 2020;4</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31184501/"" target=""_blank"">Grunenberg et al. Future Oncol. 2019;15:2687-2697.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32603202/"" target=""_blank"">Lim et al. Expert Opin Pharmacother. 2020;21:1555-1564.</a></p><p>8.23<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the evidence provided supports the efficacy of ibrutinib for the treatment of first line and relapsed/refractory WM. The Subcommittee however considered that this evidence was limited, in that it does not include randomised controlled trials comparing ibrutinib to relevant rituximab combination chemotherapy (ie. bendamustine-rituximab or DRC). The Subcommittee considered that the efficacy of rituximab in combination with chemotherapy would be considerably greater than the comparator treatment in the iNNOVATE trial (rituximab monotherapy). The Subcommittee considered the efficacy (PFS) of ibrutinib for patients with previously untreated WM to be somewhat comparable to that of bendamustine-rituximab. The Subcommittee considered that in the absence of direct comparative trials, the benefit of ibrutinib over such comparators is uncertain.</p><p>8.24<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the toxicity profile of ibrutinib to be manageable and less than that of other currently funded treatments. The Subcommittee considered that the reduced toxicity and reduced treatment burden may correspond to a health-related quality of life benefit. The Subcommittee also considered the improved suitability of ibrutinib as an oral treatment as it allows treatment in the community and management of patients as outpatients. The Subcommittee considered that, when used in combination with rituximab, outpatient attendance for systemic rituximab treatment would be required for up to 8 cycles. The Subcommittee considered that comparators for ibrutinib were of fixed duration (6 cycles) of systemic therapy versus continuous therapy with ibrutinib.</p><p>8.25<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that for first line treatment of WM, ibrutinib would be of most benefit and may improve PFS for those with comorbidities who are unfit for more intensive rituximab-based chemotherapy regimens. The Subcommittee considered that this patient group would equate to approximately 25% of those with previously untreated WM but that this may vary depending on clinician preference.</p><p>8.26<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there is unlikely to be new evidence for the use of ibrutinib for patients with WM, as BTK inhibitors are the standard of care for these patients in other international jurisdictions.</p><p>8.27<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that ibrutinib would be of particular benefit and would improve PFS for those with WM who relapse early after or are refractory to rituximab-based chemotherapy, as these individuals have very limited current treatment options.</p><p>8.28<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the publications below of key clinical trial evidence for other BTK inhibitors for the treatment of WM to assess whether there is a class effect. The Subcommittee considered that a class effect is likely, with each BTK inhibitor presenting differing side effect profiles. The Subcommittee considered that it would welcome a funding application for the use of other BTK inhibitors for this patient group.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ashpublications.org/blood/article/136/18/2038/461625/A-randomized-phase-3-trial-of-zanubrutinib-vs"" target=""_blank"">Constantine et al. Blood. 2020;136:2038-2050.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://onlinelibrary.wiley.com/doi/10.1111/cas.14561"" target=""_blank"">Sekiguchi et al. Cancer Sci. 2020;111:3327-3337.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30210-8/fulltext"" target=""_blank"">Owen et al. Lancet Haematol. 2020;7:112-121.</a></p><p>8.29<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the response to ibrutinib treatment may also depend on the identified WM mutation subtype and that those with CXCR4 mutations may benefit more than other populations. The Subcommittee considered that CXCR4 subtyping is not currently included in routine WM testing. The Subcommittee considered that there may be changes in health sector expenditure if ibrutinib were funded, with increased testing for CXCR4 mutations to determine treatment preference especially for first line therapy.\xa0</p><p>8.30<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered other health sector expenditure costs of ibrutinib would include additional clinic follow up for continuous therapy, outpatient care to manage side effects, and pharmacy dispensing services.</p><p>8.31<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that if funded, the number of patients receiving ibrutinib would increase over time due to continuous therapy and the long PFS. The Subcommittee considered that the estimated duration of treatment of 47.7 months used to assess the budget impact of ibrutinib is likely an underestimate and considered that patients with WM would likely continue treatment for longer than this. The Subcommittee noted that in the iNNOVATE trial, 45% of patients continued to receive ibrutinib in a commercial setting post-study, indicating that the duration of treatment may be much longer. The Subcommittee considered that if ibrutinib were funded, New Zealand patients may have lower discontinuation rates compared to that seen overseas and in clinical trials due to the lack of other currently funded treatment options available for WM. The Subcommittee considered that the treatment duration and disease course of WM is probably similar to the more well-evidenced CLL patient group treated with BTK inhibitors.</p><p>8.32<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that comparator treatments for patients who could receive rituximab in combination with chemotherapy would require fewer than two lines of treatment of finite duration over 5 years, consistent with the median PFS of 70 months for patients receiving bendamustine-rituximab and thus the relative cost of treatment compared with ibrutinib would likely be substantially less.</p><p>8.33<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for ibrutinib if it were to be funded in New Zealand for WM. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Subcommittee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.<span style=""color: black;""> </span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000UYtfI&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000001vfyj"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>8.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed an application from Janssen for the treatment of first line and relapsed/refractory Waldenström macroglobulinemia (WM).</p><p>8.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted correspondence from a clinician which outlines the unmet need for a BTK inhibitor to treat patients with WM, among other conditions.</p><p>8.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'fs': '<p>8.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed an application from Janssen for the treatment of first line and relapsed/refractory Waldenström macroglobulinemia (WM).</p><p>8.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted correspondence from a clinician which outlines the unmet need for a BTK inhibitor to treat patients with WM, among other conditions.</p><p>8.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Thursday 4 November 2021.', 'fs': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Thursday 4 November 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000UYtfI2AT'}, 'Id': 'a0POZ00000UYtfI2AT', 'Event_Date__c': '2022-03-11', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Thursday 4 November 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Low', 'Formatted_Date__c': 'Mar 2022', 'Published_Recommendation__c': '<p>8.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that ibrutinib for the treatment of first line Waldenström macroglobulinemia be listed with a <b>low</b> priority, within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">IBRUTINIB</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application – Waldenström Macroglobulinaemia (Lymphoplasmacytic Lymphoma)</b></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Applications only from a haematologist or any other medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months. </span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Prerequisites</b><span style=""font-size: 9pt;""> (tick boxes where appropriate):</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has Waldenström Macroglobulinaemia/Lymphoplasmacytic Lymphoma requiring treatment; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient is treatment naïve; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has good performance status.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Renewal application</b></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Applications only from a haematologist or any other medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months. </span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Prerequisites</b><span style=""font-size: 9pt;""> (tick boxes where appropriate) </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of clinical disease progression and </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains appropriate, and the patient is benefiting from treatment</span></p><p class=""ql-indent-1""><br></p><p>8.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee noted:</p><p class=""ql-indent-1"">8.5.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>the health need of people with WM requiring first line therapy, particularly in those who are unfit for immunochemotherapy and the currently funded treatment options for this population group</p><p class=""ql-indent-1"">8.5.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>the evidence of benefit and improved tolerability of ibrutinib over currently funded treatments for people with WM; although the Subcommittee recognised the absence of direct comparator randomised controlled trials</p><p class=""ql-indent-1"">8.5.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>the improved suitability of an oral treatment option for this patient group if used as monotherapy</p>', 'Published_Application__c': '<p>8.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed an application from Janssen for the treatment of first line and relapsed/refractory Waldenström macroglobulinemia (WM).</p><p>8.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted correspondence from a clinician which outlines the unmet need for a BTK inhibitor to treat patients with WM, among other conditions.</p><p>8.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'Published_Discussion__c': '<p>8.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the supplier had submitted an abbreviated clinical summary in 2018 to consider funding ibrutinib for patients with WM, which had not previously been considered by CaTSoP or PTAC. The Subcommittee noted that there have been no previous considerations of specific treatments for WM in isolation, however Pharmac currently funds several treatments for patients with indolent lymphomas (eg WM), including bendamustine and rituximab (funded under Special Authority).</p><p>8.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lymphoplasmacytic lymphoma is an incurable low-grade B-cell non-Hodgkin lymphoma characterised by the infiltration of bone marrow +/-spleen or lymph nodes by a clonal B cell population. The Subcommittee noted that when lymphoplasmacytic lymphoma is associated with an IgM paraprotein, it is referred to as Waldenström macroglobulinemia. For the purposes of the record, WM will be used to reference both lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia. (<a href=""https://www.leukaemia.org.au/blood-cancer-information/types-of-blood-cancer/waldenstroms-macroglobulinaemia/"" target=""_blank"">Leukaemia Foundation Australia 2021</a>).</p><p>8.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that WM is a heterogenous condition. The Subcommittee noted that asymptomatic patients should undergo monitoring and only require treatment if symptomatic disease develops. The Subcommittee noted that WM can cause anaemia, pancytopenia, symptomatic organomegaly or B-symptoms from tissue infiltration, and that symptomatic disease can result from IgM paraprotein associated disorders including hyperviscosity, cold agglutinin disease, peripheral neuropathy, or cryoglobulinaemia. The Subcommittee noted that these symptoms may impact an individual’s quality of life and ability to carry out daily activities. Some complications of WM require urgent therapy, such as symptomatic hyperviscosity, moderate to severe haemolytic anaemia, and symptomatic cryoglobulinemia. The Subcommittee noted that WM is a progressive disease that results in impaired function and quality of life and can lead to early death.</p><p>8.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted international estimates of WM incidence of 2-3 cases per million. The Subcommittee noted the supplier’s estimate of approximately 12 patients diagnosed with relapsed/refractory WM per year in New Zealand. The Subcommittee considered this to be an underestimate, and that patient numbers in New Zealand could be double that estimated by the supplier. The Subcommittee noted WM is more common in men, and predominantly diagnosed in older patients with a median age at diagnosis of 68 years (<a href=""https://www.leukaemia.org.au/blood-cancer-information/types-of-blood-cancer/waldenstroms-macroglobulinaemia/"" target=""_blank"">Leukaemia Foundation Australia 2021</a>). The Subcommittee noted that the relative incidence of WM in Māori and other disadvantaged groups compared to non-Māori was uncertain.</p><p>8.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the currently funded treatments for those with WM include bendamustine-rituximab (preferred option), and rituximab- cyclophosphamide-dexamethasone (DRC), or rituximab monotherapy (in those with comorbidities or low tumour burden). The Subcommittee noted that the median progression free survival (PFS) is 69.5 months for\xa0bendamustine-rituximab treatment (<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61763-2/fulltext"" target=""_blank"">Rummel et al. Lancet. 2013;381:1203-1210</a>), 34 months (95% CI 23 to ‘not reached’) for first line DRC treatment (<a href=""https://ashpublications.org/blood/article/126/11/1392/34400/Dexamethasone-rituximab-and-cyclophosphamide-as"" target=""_blank"">Kastritis et al. Blood. 2015;126:1392-1394</a>),), and 35 months (95% CI 15 to 51) for DRC treatment in relapsed/refractory patients (<a href=""https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14826"" target=""_blank"">Paludo et al. BJH. 2017;179:98-105</a>), and 20.3 months for 8 cycles of single agent rituximab (comparator arm of iNNOVATE trial). The Subcommittee considered that patients with relapsed/refractory WM can be retreated with the previous chemotherapy regimen if this was effective in the previous line, an alternative chemotherapy regimen, or rituximab monotherapy. The Subcommittee considered that efficacy of treatment and PFS with each successive line of treatment would be expected to diminish. The Subcommittee noted that autologous or allogenic transplantation were infrequent therapies for patients with WM.</p><p>8.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following publications as evidence of the use of currently funded agents for the treatment of WM:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.dovepress.com/rituximab-based-combination-therapy-in-patients-with-waldenstroumlm-ma-peer-reviewed-fulltext-article-OTT"" target=""_blank"">Zheng et al. Onco Targets Ther. 2019;12:2751-2766</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Walewski et al. Br J Haematol. 2020;188;898-906</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.15718"" target=""_blank"">Laribi et al. Br J Haematol. 2018;186:146-149</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ashpublications.org/blood/article/126/11/1392/34400/Dexamethasone-rituximab-and-cyclophosphamide-as"" target=""_blank"">Kastritis et al. Blood. 2015;126:1392-4</a></p><p>8.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that bortezomib in combination with dexamethasone +/- rituximab has also been shown to be efficacious in patients with WM. It was noted that the long term follow up of a phase II study of bortezomib, dexamethasone, and rituximab (BDR) has shown a median PFS of 3.5 years, median duration of major response of 5.5 years, and OS rate of 66% at 7 years (<a href=""https://www.annalsofoncology.org/article/S0923-7534(19)31695-3/pdf"" target=""_blank"">Kastritis et al. ESMO. 2018</a>; <a href=""https://ashpublications.org/blood/article/129/4/456/36177/BDR-in-newly-diagnosed-patients-with-WM-final"" target=""_blank"">Gavriatopoulou et al. Blood. 2017;4:456-459</a>). The Subcommittee noted that bortezomib is not currently funded for people with WM and considered that it would like to review bortezomib for the treatment of patients with WM at a future Cancer Treatments Subcommittee meeting.</p><p>8.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted elderly patients with WM are more likely to have poorer outcomes due to their increased frailty, comorbidities, and susceptibility to developing adverse reactions to chemotherapy (<a href=""https://ashpublications.org/blood/article/113/18/4163/25738/International-prognostic-scoring-system-for"" target=""_blank"">Morel et al. Blood. 2009;113:4163-70</a>). The Subcommittee also noted those with WM living in rural areas are more likely to experience difficulty in accessing treatment services and thereby more at risk of experiencing poor survival and health outcomes. The Subcommittee considered that the availability of an effective oral treatment option for this patient group would be particularly beneficial.</p><p>8.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the treatment options (rituximab in combination with chemotherapy) to be effective for fit patients with WM and therefore the health need for this group of treatment naïve patients was comparatively low. The Subcommittee considered that the health need for patients with WM is greater for those who are unfit or unable to receive rituximab in combination with chemotherapy due to their frailty or comorbidities, as well as those who have relapsed after, or are refractory to a prior line of treatment, due to the limited treatment options and shorter PFS in later lines of treatment.</p><p>8.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that ibrutinib is an inhibitor of Bruton tyrosine kinase (BTK), and effectively inhibits B-cell receptor and cytokine receptor pathways, thereby hindering malignant B-cell proliferation and survival <i>in vivo</i> as well as cell migration and substrate adhesion in vitro. The Subcommittee noted that <a href=""https://www.medsafe.govt.nz/regulatory/ProductDetail.asp?ID=17325"" target=""_blank"">ibrutinib is Medsafe approved</a> for the treatment of patients with WM. The Subcommittee noted that the recommended dose of ibrutinib for WM is 420mg (three 140mg capsules) once daily until disease progression or if no longer tolerated by the patient, administered either as monotherapy or in combination with rituximab.</p><p>8.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that as ibrutinib can be self-administered by the patient or caregiver in the community, the burden of treatment delivery and need for repeated attendance at a hospital or outpatient facility would be reduced.</p><p>8.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the key evidence for ibrutinib in the treatment of WM comes from two clinical trials, PCYC-1127-CA (iNNOVATE) and PCYC-1118E.</p><p>8.18<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted that the iNNOVATE trial was a phase III randomised, double-blind, placebo-controlled trial which investigated ibrutinib plus rituximab compared to placebo plus rituximab in 150 adults with previously untreated (n=68) or treated (n=82) WM.</p><p class=""ql-indent-1"">8.18.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted the results of the final analysis of the iNNOVATE trial after a median follow up of 50 (range 0.5-63) months. The Subcommittee noted that the overall median PFS was not reached (95% CI 57.7 months to ‘not evaluable’ [NE]) in the ibrutinib-rituximab group and 20.3 months (95% CI 13.0 to 27.6) in the placebo-rituximab group. The Subcommittee noted that the median time to next treatment was not reached in the ibrutinib-rituximab group and 18 months in the placebo-rituximab group. The Subcommittee noted that the overall survival (OS) was not reached in either arm. The Subcommittee noted that the ibrutinib-rituximab group had a sustained haemoglobin improvement of 77% versus 43% in the placebo-rituximab group (P&lt;0.0001) (<a href=""https://ascopubs.org/doi/full/10.1200/JCO.21.00838"" target=""_blank"">Buske et al. J Clin Oncol. 2021</a>).</p><p class=""ql-indent-1"">8.18.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that in previously untreated patients, the 54-month PFS rate was not reached in either the ibrutinib-rituximab or placebo-rituximab arm, and that the 48-month PFS rate in these subgroups was 70% and 32%, respectively. It was noted that in previously treated patients, the 54-month PFS rate was 68% with ibrutinib-rituximab versus 20% with placebo-rituximab, with 48-month PFS rates of 71% and 20%, respectively. The Subcommittee noted that ibrutinib-rituximab treatment significantly reduced risk of progression or death versus placebo-rituximab across all prespecified subgroups within the previously treated population, including by serum IgM level, haemoglobin level, and MYD88 mutational status, and within most of these subgroups in the previously untreated population.</p><p class=""ql-indent-1"">8.18.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that serious adverse events (AEs) occurred in 53% of the ibrutinib-rituximab group, 33% of the placebo-rituximab group, and 52% of the ibrutinib substudy group. The Subcommittee noted that the most common AEs in the ibrutinib substudy group were infections (47% at years 3-4; 50% at years 4-5), hypertension (29% at years 3-4; 36% at years 4-5), and diarrhoea (24% in years 3-4; 7% in years 4-5). The Subcommittee noted that 7 patients in the ibrutinib-rituximab group and 34 patients in the placebo-rituximab group discontinued treatment due to disease progression.</p><p class=""ql-indent-1"">8.18.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted 31 patients from the iNNOVATE trial who were refractory to treatment with rituximab were enrolled into an open label ibrutinib monotherapy substudy. The Subcommittee noted the results of the final analysis of the open label ibrutinib monotherapy substudy after a median follow up of 58 (range 9-61) months. The Subcommittee noted that the median PFS was 39 months (95% CI 25 to NE), with an estimated 18-month PFS of 86% and estimated 60-month PFS rate of 40%. The median OS was not reached (95% CI NE to NE) and the 60-month OS rate was 73% <a href=""https://clincancerres.aacrjournals.org/content/early/2021/08/17/1078-0432.CCR-21-1497.full-text.pdf"" target=""_blank"">Trotman et al. Clin Cancer Res. 2021</a>).</p><p>8.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted the following additional publications on the iNNOVATE trial:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30632-5/fulltext"" target=""_blank"">Dimopoulos et al. Lancet Oncol. 2017;18:241-250.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.nejm.org/doi/10.1056/NEJMoa1802917?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov"" target=""_blank"">Dimopoulos et al. N Engl J Med. 2018;378:2399-2410.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8018"" target=""_blank"">Trotman et al. EHA. 2017 abstract.</a></p><p>8.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the PCYC-1118E trial was a phase II open-label, prospective, single agent study which investigated ibrutinib monotherapy until disease progression or unacceptable toxicity in 63 symptomatic adults with WM who have received at least one prior treatment (median of two prior treatments) (<a href=""https://ascopubs.org/doi/10.1200/JCO.20.00555?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed"" target=""_blank"">Treon et al. J Clin Oncol. 2021;39:565-575.</a>; <a href=""https://www.nejm.org/doi/10.1056/NEJMoa1501548?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov"" target=""_blank"">Treon et al. N Engl J Med. 2015; 372:1430-40.</a>). The Subcommittee noted that after a median follow up of 59 months (95% CI 40 to 60), the 5-year PFS was 54% (95% CI 39 to 67) and the 5-year OS was 87%. The Subcommittee noted that the overall response rate (ORR) was 90.5% and the major response rate was 79.4%. The Subcommittee noted that the most common grade 3 or higher AEs that occurred in more than one patient were neutropenia (15.9%), thrombocytopenia (11.1%), and pneumonia (3.2%). The Subcommittee noted that atrial fibrillation occurred in eight patients (12.7%) overall at a median of 15 months (range 3-38 months) after starting treatment.</p><p>8.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that Castillo et al 2021 reported on a phase II, single centre, prospective, single arm study which investigated ibrutinib monotherapy in 30 treatment naïve patients with WM (<a href=""https://www.nature.com/articles/s41375-021-01417-9"" target=""_blank"">Castillo et al. Leukaemia. 2021</a>). The Subcommittee noted that after a median follow up of 50 months, the median PFS was not reached and the 4-year PFS rate was 76%, and there was a non-significant lower 4-year PFS rate in patients with than without CXCR4 mutations (59% versus 92%; P=0.06). The Subcommittee noted that the most common treatment-related AEs were fatigue, upper respiratory infection, and hematoma, and that atrial fibrillation occurred in 20% of patients.</p><p>8.22<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the additional evidence supporting the use of ibrutinib for patients with WM:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""http://www.waldenstroms.com/images/news/ASH-2017/12-11-2017-PUB4051.pdf"" target=""_blank"">Gustine, J., K. Meid, and T. Dubeau. American Society of Hematology. 2017 abstract</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.semanticscholar.org/paper/Ibrutinib-Is-Highly-Active-As-First-Line-Therapy-in-Treon-Gustine/b5b5f8b55a1a4109ea279d6318736350219fc4ad"" target=""_blank"">Treon et al. ASH. 2017 abstract</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306303/"" target=""_blank"">Castillo et al. Hemasphere. 2020;4</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31184501/"" target=""_blank"">Grunenberg et al. Future Oncol. 2019;15:2687-2697.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32603202/"" target=""_blank"">Lim et al. Expert Opin Pharmacother. 2020;21:1555-1564.</a></p><p>8.23<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the evidence provided supports the efficacy of ibrutinib for the treatment of first line and relapsed/refractory WM. The Subcommittee however considered that this evidence was limited, in that it does not include randomised controlled trials comparing ibrutinib to relevant rituximab combination chemotherapy (ie. bendamustine-rituximab or DRC). The Subcommittee considered that the efficacy of rituximab in combination with chemotherapy would be considerably greater than the comparator treatment in the iNNOVATE trial (rituximab monotherapy). The Subcommittee considered the efficacy (PFS) of ibrutinib for patients with previously untreated WM to be somewhat comparable to that of bendamustine-rituximab. The Subcommittee considered that in the absence of direct comparative trials, the benefit of ibrutinib over such comparators is uncertain.</p><p>8.24<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the toxicity profile of ibrutinib to be manageable and less than that of other currently funded treatments. The Subcommittee considered that the reduced toxicity and reduced treatment burden may correspond to a health-related quality of life benefit. The Subcommittee also considered the improved suitability of ibrutinib as an oral treatment as it allows treatment in the community and management of patients as outpatients. The Subcommittee considered that, when used in combination with rituximab, outpatient attendance for systemic rituximab treatment would be required for up to 8 cycles. The Subcommittee considered that comparators for ibrutinib were of fixed duration (6 cycles) of systemic therapy versus continuous therapy with ibrutinib.</p><p>8.25<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that for first line treatment of WM, ibrutinib would be of most benefit and may improve PFS for those with comorbidities who are unfit for more intensive rituximab-based chemotherapy regimens. The Subcommittee considered that this patient group would equate to approximately 25% of those with previously untreated WM but that this may vary depending on clinician preference.</p><p>8.26<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there is unlikely to be new evidence for the use of ibrutinib for patients with WM, as BTK inhibitors are the standard of care for these patients in other international jurisdictions.</p><p>8.27<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that ibrutinib would be of particular benefit and would improve PFS for those with WM who relapse early after or are refractory to rituximab-based chemotherapy, as these individuals have very limited current treatment options.</p><p>8.28<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the publications below of key clinical trial evidence for other BTK inhibitors for the treatment of WM to assess whether there is a class effect. The Subcommittee considered that a class effect is likely, with each BTK inhibitor presenting differing side effect profiles. The Subcommittee considered that it would welcome a funding application for the use of other BTK inhibitors for this patient group.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ashpublications.org/blood/article/136/18/2038/461625/A-randomized-phase-3-trial-of-zanubrutinib-vs"" target=""_blank"">Constantine et al. Blood. 2020;136:2038-2050.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://onlinelibrary.wiley.com/doi/10.1111/cas.14561"" target=""_blank"">Sekiguchi et al. Cancer Sci. 2020;111:3327-3337.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30210-8/fulltext"" target=""_blank"">Owen et al. Lancet Haematol. 2020;7:112-121.</a></p><p>8.29<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the response to ibrutinib treatment may also depend on the identified WM mutation subtype and that those with CXCR4 mutations may benefit more than other populations. The Subcommittee considered that CXCR4 subtyping is not currently included in routine WM testing. The Subcommittee considered that there may be changes in health sector expenditure if ibrutinib were funded, with increased testing for CXCR4 mutations to determine treatment preference especially for first line therapy.\xa0</p><p>8.30<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered other health sector expenditure costs of ibrutinib would include additional clinic follow up for continuous therapy, outpatient care to manage side effects, and pharmacy dispensing services.</p><p>8.31<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that if funded, the number of patients receiving ibrutinib would increase over time due to continuous therapy and the long PFS. The Subcommittee considered that the estimated duration of treatment of 47.7 months used to assess the budget impact of ibrutinib is likely an underestimate and considered that patients with WM would likely continue treatment for longer than this. The Subcommittee noted that in the iNNOVATE trial, 45% of patients continued to receive ibrutinib in a commercial setting post-study, indicating that the duration of treatment may be much longer. The Subcommittee considered that if ibrutinib were funded, New Zealand patients may have lower discontinuation rates compared to that seen overseas and in clinical trials due to the lack of other currently funded treatment options available for WM. The Subcommittee considered that the treatment duration and disease course of WM is probably similar to the more well-evidenced CLL patient group treated with BTK inhibitors.</p><p>8.32<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that comparator treatments for patients who could receive rituximab in combination with chemotherapy would require fewer than two lines of treatment of finite duration over 5 years, consistent with the median PFS of 70 months for patients receiving bendamustine-rituximab and thus the relative cost of treatment compared with ibrutinib would likely be substantially less.</p><p>8.33<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for ibrutinib if it were to be funded in New Zealand for WM. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Subcommittee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.<span style=""color: black;""> </span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000UYtfI&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000001vfyj"" alt=""image.png""></img></p>', 'Status_History__c': 'a132P000000DbnFQAS'}, 'change': None}]",May 2021,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000UYtfJ2AT'}, 'Id': 'a0POZ00000UYtfJ2AT', 'Event_Date__c': '2022-03-31', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2022', 'Status_History__c': 'a132P000000EDZTQA4'}, 'change': None}]",Mar 2022,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
